Synakis

Developer of a biodegradable hydrogel vitreous substitute intended to transform the treatment of retinal detachment and similar conditions which use vitreous substitutes. The company’s platform is commercializing and translating vitreous substitutes into an injectable, non-cytotoxic in vitro and in vivo, surgical device, enabling low-swelling, stable, and optically transparent with a refractive index and density similar…